{"protocolSection":{"identificationModule":{"nctId":"NCT02308020","orgStudyIdInfo":{"id":"15450"},"secondaryIdInfos":[{"id":"I3Y-MC-JPBO","type":"OTHER","domain":"Eli Lilly and Company"},{"id":"2014-004010-28","type":"EUDRACT_NUMBER"}],"organization":{"fullName":"Eli Lilly and Company","class":"INDUSTRY"},"briefTitle":"A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain","officialTitle":"A Phase 2 Study of Abemaciclib in Patients With Brain Metastases Secondary to Hormone Receptor Positive Breast Cancer, Non-small Cell Lung Cancer, or Melanoma"},"statusModule":{"statusVerifiedDate":"2020-12","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":true,"nctId":"NCT03763604","statusForNctId":"APPROVED_FOR_MARKETING"},"startDateStruct":{"date":"2015-04-20","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2018-11-08","type":"ACTUAL"},"completionDateStruct":{"date":"2019-11-08","type":"ACTUAL"},"studyFirstSubmitDate":"2014-12-02","studyFirstSubmitQcDate":"2014-12-02","studyFirstPostDateStruct":{"date":"2014-12-04","type":"ESTIMATED"},"resultsFirstSubmitDate":"2019-11-06","resultsFirstSubmitQcDate":"2019-12-17","resultsFirstPostDateStruct":{"date":"2019-12-19","type":"ACTUAL"},"lastUpdateSubmitDate":"2020-12-17","lastUpdatePostDateStruct":{"date":"2020-12-19","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Eli Lilly and Company","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"The main purpose of this study is to evaluate the safety and effectiveness of the study drug known as abemaciclib in participants with hormone receptor positive breast cancer, non-small cell lung cancer (NSCLC), or melanoma that has spread to the brain."},"conditionsModule":{"conditions":["Breast Cancer","Non-small Cell Lung Cancer","Melanoma","Brain Metastases"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"NON_RANDOMIZED","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":162,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Part A Abemaciclib: HR+, HER2+ Breast Cancer","type":"EXPERIMENTAL","description":"Abemaciclib 200 milligram (mg) was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or in combination with endocrine therapy (ET). Participants with hormone receptor positive (HR+), HER2+ breast cancer receiving concurrent trastuzumab, 150 mg abemaciclib was given orally once every 12 hours on days 1-21 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.","interventionNames":["Drug: Abemaciclib"]},{"label":"Part B Abemaciclib: HR+, HER2- Breast Cancer","type":"EXPERIMENTAL","description":"Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or for participants in combination with endocrine therapy (ET).\n\nParticipants may continue to receive treatment until discontinuation criteria are met.","interventionNames":["Drug: Abemaciclib"]},{"label":"Part C Abemaciclib: Surgical Resection","type":"EXPERIMENTAL","description":"Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or for participants with breast cancer in combination with endocrine therapy (ET). Participants with HR+, HER2+ breast cancer, NSCLC, or melanoma with intracranial lesions for which surgical resection is clinically indicated receiving concurrent trastuzumab, gemcitabine, or pemetrexed, 150 mg abemaciclib was given orally once every 12 hours for 5-14 days prior to surgical resection. Dosing may resume following wound healing on a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.","interventionNames":["Drug: Abemaciclib"]},{"label":"Part D Abemaciclib: Non-Small Cell Lung Cancer (NSCLC)","type":"EXPERIMENTAL","description":"Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle. Participants with NSCLC receiving concurrent gemcitabine or pemetrexed, 150 mg abemaciclib was given orally once every 12 hours on days 1-21 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.","interventionNames":["Drug: Abemaciclib"]},{"label":"Part E Abemaciclib: Melanoma","type":"EXPERIMENTAL","description":"Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.","interventionNames":["Drug: Abemaciclib"]},{"label":"Part F Abemaciclib: HR+ Breast Cancer, NSCLC, or Melanoma","type":"EXPERIMENTAL","description":"Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or for participants with breast cancer in combination with endocrine therapy (ET). Participants with HR+ (either HER2+ or HER2-) breast cancer, NSCLC, or melanoma and leptomeningeal metastases received concurrent trastuzumab, gemcitabine, or pemetrexed, 150 mg abemaciclib was given orally once every 12 hours on days 1-21 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.","interventionNames":["Drug: Abemaciclib"]}],"interventions":[{"type":"DRUG","name":"Abemaciclib","description":"Administered orally","armGroupLabels":["Part A Abemaciclib: HR+, HER2+ Breast Cancer","Part B Abemaciclib: HR+, HER2- Breast Cancer","Part C Abemaciclib: Surgical Resection","Part D Abemaciclib: Non-Small Cell Lung Cancer (NSCLC)","Part E Abemaciclib: Melanoma","Part F Abemaciclib: HR+ Breast Cancer, NSCLC, or Melanoma"],"otherNames":["LY2835219"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR): Objective Intracranial Response Rate (OIRR)","description":"OIRR is the percentage of participants with a (CR) or (PR) based on the Response Assessment in Neuro-Oncology Brain Metastasis (RANO-BM) response criteria. CR is measurable target lesions, the disappearance of all central nervous system (CNS) target lesions for at least 4 weeks; no new lesions; no corticosteroids; stable or improved clinically. PR is at least a 30% decrease in the sum longest duration (LD) of CNS target lesions, taking as reference the baseline sum LD for at least 4 weeks; no new lesions; stable to decreased corticosteroid dose; stable or improved clinically. Nontarget lesions requires disappearance CNS non-target lesions and no new CNS lesions. Stable disease (SD) is less than (\\<)30% decrease relative to baseline but \\<20% increase in sum LD relative to nadir. Progressive disease (PD) is greater than or equal to (≥) 20% increase in sum LD relative to nadir and a relative increase of 20%, ≥1 lesion must increase by absolute value of ≥5 millimeter (mm).","timeFrame":"Baseline to Objective Disease Progression (Up to 36 Months)"}],"secondaryOutcomes":[{"measure":"Percentage of Participants With CR, PR, Stable Disease (SD), Progressive Disease (PD), or Not Evaluable (NE): Best Overall Intracranial Response (BOIR)","description":"Percentage of Participants with BOIR was categorized as CR, PR, SD, PD or NE, as defined by RANO-BM, from baseline until the earliest of objective progression according to brain metastases response criteria or start of new anticancer therapy. CR is measurable target lesions, the disappearance of all CNS target lesions for at least 4 weeks; no new lesions; no corticosteroids; stable or improved clinically. PR is at least a 30% decrease in the sum LD of CNS target lesions, taking as reference the baseline sum LD for at least 4 weeks; no new lesions; stable to decreased corticosteroid dose; stable or improved clinically. SD is \\<30% decrease relative to baseline but \\<20% increase in sum LD relative to nadir. PD is greater than or equal to (≥) 20% increase in sum LD relative to nadir and a relative increase of 20%, ≥1 lesion must increase by absolute value of ≥5 mm. NE is absent (no abnormality; normal), or non-evaluable (NE).","timeFrame":"Baseline to Earliest Objective Progression or Start of New Anticancer Therapy (Up to 36 Months)"},{"measure":"Duration of CR or PR: Duration of Intracranial Response (DOIR)","description":"DOIR is measured from the date of first evidence of a confirmed response (CR or PR), as defined by RANO-BM, to the date objective progression or death from any cause. CR is measurable target lesions, the disappearance of all CNS target lesions for at least 4 weeks; no new lesions; no corticosteroids; stable or improved clinically. PR is at least a 30% decrease in the sum LD of CNS target lesions, taking as reference the baseline sum LD for at least 4 weeks; no new lesions; stable to decreased corticosteroid dose; stable or improved clinically. Participants who have neither progressed nor died were censored on the day of their last radiographic tumor assessment or on the date of response. PD is greater than or equal to (≥) 20% increase in sum LD relative to nadir and a relative increase of 20%, ≥1 lesion must increase by absolute value of ≥5 mm. DOIR was summarized using Kaplan-Meier estimates.","timeFrame":"Date of CR or PR to Date of Objective Disease Progression or Death from Any Cause (Up to 36 Months)"},{"measure":"Percentage of Participants With Best Overall Intracranial Response (BOIR) of CR, PR, or SD: Intracranial Disease Control Rate (IDCR)","description":"Percentage of participants with BOIR of CR, PR, or SD: IDCR, as defined by RANO-BM is reported. CR is measurable target lesions, the disappearance of all central nervous system CNS target lesions for at least 4 weeks; no new lesions; no corticosteroids; stable or improved clinically. PR is at least a 30% decrease in the sum LD of CNS target lesions, taking as reference the baseline sum LD for at least 4 weeks; no new lesions; stable to decreased corticosteroid dose; stable or improved clinically. Nontarget lesions requires disappearance CNS non-target lesions and no new CNS lesions. SD is less than (\\<)30% decrease relative to baseline but \\<20% increase in sum LD relative to nadir. PD is greater than or equal to (≥) 20% increase in sum LD relative to nadir and a relative increase of 20%, ≥1 lesion must increase by absolute value of ≥5 mm.","timeFrame":"Baseline to Disease Progression or Start of New Anticancer Therapy (Up to 36 Months)"},{"measure":"Percentage of Participants With BOIR of CR, PR, or SD With Duration of SD for at Least 6 Months: Intracranial Clinical Benefit Rate (ICBR)","description":"ICBR is the percentage of participants with BOIR of CR, PR, or SD with duration of SD for at least 6 months, as defined by RANO-BM. CR is measurable target lesions, the disappearance of all CNS target lesions for at least 4 weeks; no new lesions; no corticosteroids; stable or improved clinically. PR is at least a 30% decrease in the sum LD of CNS target lesions, taking as reference the baseline sum LD for at least 4 weeks; no new lesions; stable to decreased corticosteroid dose; stable or improved clinically. SD is \\<30% decrease relative to baseline but \\<20% increase in sum LD relative to nadir. PD is greater than or equal to (≥) 20% increase in sum LD relative to nadir and a relative increase of 20%, ≥1 lesion must increase by absolute value of ≥5 mm.","timeFrame":"Baseline to Disease Progression or Start of New Anticancer Therapy (Up to 36 Months)"},{"measure":"Overall Survival (OS)","description":"OS was measured from baseline to the date of death from any cause. For each participant who is not known to have died as of the data-inclusion cutoff date for a particular analysis, OS was censored for that analysis at the date of last contact prior to the data inclusion cutoff date (contacts considered in the determination of last contact date include adverse event (AE) date, tumor assessment date, visit date, and last known alive date). OS was summarized using Kaplan-Meier estimates.","timeFrame":"Baseline to the Date of Death from Any Cause (Up to 5 Years)"},{"measure":"Percentage of Participants With a Best Response of CR or PR: Extracranial Objective Response Rate (EORR)","description":"The percentage of participants with a best response of CR or PR objective response rate is complete response (CR) + partial response (PR), as classified by the investigators according to the Response Evaluation Criteria In Solid Tumors (RECIST v1.1) guidelines. CR is disappearance of all target and non-target lesions; PR is ≥30% decrease in sum of longest diameter of target lesions. PD is defined as at least a 20% increase in the sum LD of CNS target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study) and the 20% increase must be at least one lesion must increase by an absolute value of ≥5 mm to be considered progression.","timeFrame":"Baseline to Disease Progression (Up to 36 Months)"},{"measure":"Percentage of Participants With a Best Overall Response of CR, PR, or SD: Extracranial Disease Control Rate (EDCR)","description":"Disease control rate (DCR) (CR+ PR+ SD) per RECIST v1.1. is defined as the percentage of participants with best overall response of CR, PR, or SD. CR is disappearance of all target and non-target lesions; PR is ≥30% decrease in sum of longest diameter of target lesions. PD is defined as at least a 20% increase in the sum LD of CNS target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study) and the 20% increase must be at least one lesion must increase by an absolute value of ≥5 mm to be considered progression.","timeFrame":"Baseline to Disease Progression or Start of New Anticancer Therapy (Up to 36 Months)"},{"measure":"Progression Free Survival (PFS) Bi-compartmental","description":"PFS was measured from baseline to objective progression (intracranial or extracranial) as defined by (RANO-BM.) or death from any cause. Participants who have neither progressed nor died were censored at the day of their last radiographic tumor assessment. PD is greater than or equal to (≥) 20% increase in sum LD relative to nadir and a relative increase of 20%, ≥1 lesion must increase by absolute value of ≥5 mm. PFS was summarized using Kaplan-Meier estimates.","timeFrame":"Baseline to Objective Disease Progression or Death from Any Cause (Up to 36 Months)"},{"measure":"Change From Baseline in Neurologic Symptoms on the MD Anderson Inventory-Brain Tumor (MDASI-BT) Subscale","description":"The MDASI-BT is an instrument to assess multi-symptoms in participants with brain tumor metastases (including those with brain metastases secondary to breast cancer). The MDASI-BT of participants with a change from baseline is reported as mean core symptoms, mean brain tumor symptoms, and symptom groupings (mean focal neurologic deficit, mean generalized/disease status symptoms, and mean gastrointestinal symptoms). The mean of all symptom subscale items was calculated where 0 equals \"not present\" and 10 equals \"as bad as you can imagine.\" A change from baseline with negative values indicate improvement, positive values indicate worsening.","timeFrame":"Baseline, Cycle 3 (Up to 63 Days)"},{"measure":"Pharmacokinetics (PK): Steady State Minimum Concentration (Cmin) of Abemaciclib and Its Metabolites LSN2839567 (M2), LSN3106726 (M20), and LSN3106729 (M18)","description":"A PK plasma sample was taken prior to abemaciclib dose to analyze the minimum concentrations of abemaciclib and its metabolites (Cmin) - Individual Cmin values were averaged if there were 3 or more available data points, otherwise individual data are reported.","timeFrame":"Parts A, B, D, E, F, Cycle 3, Day 1: Predose; Part C, Cycle 4, Day 1: Predose"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Have brain metastases secondary to hormone receptor positive breast cancer, NSCLC, or melanoma.\n* Have either human epidermal growth factor receptor 2 positive (HER2+) (Study Part A) or negative HER2- (Study Part B) breast cancer.\n* Participants in Study Part C must have HR+ breast cancer, NSCLC, or melanoma with brain lesions clinically indicated for surgical resection as well as consent to provide tissue for drug concentration determination after 5 to 14 days of study drug dosing.\n* Participants in Part D must have NSCLC of any subtype.\n* Participants in Part E must have melanoma of any subtype.\n* Participants in Part F must have HR+ breast cancer, NSCLC, or melanoma with leptomeningeal metastases.\n* For Parts A, B, D, and E: Must have at least 1 measurable brain lesion ≥10 millimeters (mm) in the longest diameter (LD).\n* For Part C (surgical): Have metastatic brain lesion(s) for which surgical resection is clinically indicated.\n* Have completed local therapy (surgical resection, whole-breast radiotherapy (WBRT), or SRS) ≥14 days prior to initiating abemaciclib and recovered from all acute effects.\n* If receiving concomitant corticosteroids, must be on a stable or decreasing dose for at least 7 days prior to the baseline Gd-MRI.\n* Have a Karnofsky performance status of ≥70.\n* Have a life expectancy ≥12 weeks.\n* For HR+ breast cancer participants in part A, B, C, and F: If currently receiving endocrine therapy, a participant may continue to receive the same endocrine therapy provided that extracranial disease is stable for at least 3 months and central nervous system (CNS) disease progression has occurred while on this endocrine therapy. If these conditions are not met, participants must discontinue endocrine therapy prior to initiation of abemaciclib.\n* For HER2+ breast cancer participants in parts A, C, and F: participants may receive concurrent treatment (ongoing or initiated simultaneously with abemaciclib) with IV trastuzumab.\n* For NSCLC participants in parts C, D, and F: if currently receiving gemcitabine or pemetrexed (single-agent or in combination with another therapy), a participant may continue to receive 1 of these 2 therapies provided that extracranial disease is stable for at least 6 weeks and CNS disease progression has occurred while on this therapy.\n* Have adequate organ function.\n\nExclusion Criteria:\n\n* Require immediate local therapy, including but not limited to WBRT, SRS, or surgical resection, for treatment of brain metastases.\n* Are taking concurrent enzyme-inducing antiepileptic drugs (EIAED).\n* Have evidence of significant (ie, symptomatic) intracranial hemorrhage.\n* For Parts A, B, C, D, E: Have evidence of leptomeningeal metastases. Note: discrete dural metastases are permitted.\n* Have experienced \\>2 seizures within 4 weeks prior to study entry.\n* For Parts A, B, D, E, and F: Have previously received treatment with any cyclin dependent kinase 6 (CDK6) inhibitor. For Part C participants may have received prior palbociclib or ribociclib, but not abemaciclib treatment.\n* Have known contraindication to Gd-MRI.\n* Have a preexisting chronic condition resulting in persistent diarrhea.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Call 1-877-CTLILLY (1-877-285-459) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)","affiliation":"Eli Lilly and Company","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"City of Hope National Medical Center","city":"Duarte","state":"California","zip":"91010","country":"United States","geoPoint":{"lat":34.13945,"lon":-117.97729}},{"facility":"University of California - San Diego","city":"La Jolla","state":"California","zip":"92037-0845","country":"United States","geoPoint":{"lat":32.84727,"lon":-117.2742}},{"facility":"Univ of California San Francisco","city":"San Francisco","state":"California","zip":"94115","country":"United States","geoPoint":{"lat":37.77493,"lon":-122.41942}},{"facility":"John Wayne Cancer Institute","city":"Santa Monica","state":"California","zip":"90404","country":"United States","geoPoint":{"lat":34.01949,"lon":-118.49138}},{"facility":"University of Colorado","city":"Aurora","state":"Colorado","zip":"80045","country":"United States","geoPoint":{"lat":39.72943,"lon":-104.83192}},{"facility":"Georgetown University Medical Center","city":"Washington D.C.","state":"District of Columbia","zip":"20007","country":"United States","geoPoint":{"lat":38.89511,"lon":-77.03637}},{"facility":"Florida Cancer Specialists","city":"Fort Myers","state":"Florida","zip":"33916-2233","country":"United States","geoPoint":{"lat":26.62168,"lon":-81.84059}},{"facility":"H Lee Moffitt Cancer Center","city":"Tampa","state":"Florida","zip":"33612-9497","country":"United States","geoPoint":{"lat":27.94752,"lon":-82.45843}},{"facility":"Kaiser Permanente Center for Health Research","city":"Honolulu","state":"Hawaii","zip":"96819","country":"United States","geoPoint":{"lat":21.30694,"lon":-157.85833}},{"facility":"James Graham Brown Cancer Center","city":"Louisville","state":"Kentucky","zip":"40202","country":"United States","geoPoint":{"lat":38.25424,"lon":-85.75941}},{"facility":"Dana Farber Cancer Institute","city":"Boston","state":"Massachusetts","zip":"02215","country":"United States","geoPoint":{"lat":42.35843,"lon":-71.05977}},{"facility":"University of Michigan","city":"Ann Arbor","state":"Michigan","zip":"48109","country":"United States","geoPoint":{"lat":42.27756,"lon":-83.74088}},{"facility":"Washington University Medical Center","city":"St Louis","state":"Missouri","zip":"63110","country":"United States","geoPoint":{"lat":38.62727,"lon":-90.19789}},{"facility":"Memorial Sloan Kettering Cancer Center","city":"New York","state":"New York","zip":"10065","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"University of North Carolina at Chapel Hill","city":"Chapel Hill","state":"North Carolina","zip":"27599","country":"United States","geoPoint":{"lat":35.9132,"lon":-79.05584}},{"facility":"Providence Health and Services","city":"Portland","state":"Oregon","zip":"97213","country":"United States","geoPoint":{"lat":45.52345,"lon":-122.67621}},{"facility":"SMO Sarah Cannon Research Inst.","city":"Nashville","state":"Tennessee","zip":"37203","country":"United States","geoPoint":{"lat":36.16589,"lon":-86.78444}},{"facility":"Tennessee Oncology PLLC","city":"Nashville","state":"Tennessee","zip":"37203","country":"United States","geoPoint":{"lat":36.16589,"lon":-86.78444}},{"facility":"University of Texas MD Anderson Cancer Center","city":"Houston","state":"Texas","zip":"77030","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Nedlands","zip":"6009","country":"Australia","geoPoint":{"lat":-31.98184,"lon":115.8073}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Newcastle","zip":"2298","country":"Australia","geoPoint":{"lat":-32.92953,"lon":151.7801}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Southport","zip":"4215","country":"Australia","geoPoint":{"lat":-27.96724,"lon":153.39796}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Woolloongabba","zip":"4102","country":"Australia","geoPoint":{"lat":-27.48855,"lon":153.03655}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Vienna","zip":"1090","country":"Austria","geoPoint":{"lat":48.20849,"lon":16.37208}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Brussels","zip":"1000","country":"Belgium","geoPoint":{"lat":50.85045,"lon":4.34878}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Charleroi","zip":"6000","country":"Belgium","geoPoint":{"lat":50.41136,"lon":4.44448}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Leuven","zip":"3000","country":"Belgium","geoPoint":{"lat":50.87959,"lon":4.70093}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Liège","zip":"4000","country":"Belgium","geoPoint":{"lat":50.63373,"lon":5.56749}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.","city":"Ottawa","zip":"K1H 8L6","country":"Canada","geoPoint":{"lat":45.41117,"lon":-75.69812}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Lille","zip":"59020","country":"France","geoPoint":{"lat":50.63391,"lon":3.05512}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Lille","zip":"59037","country":"France","geoPoint":{"lat":50.63391,"lon":3.05512}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Lyon","zip":"69373","country":"France","geoPoint":{"lat":45.74906,"lon":4.84789}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Paris","zip":"75248","country":"France","geoPoint":{"lat":48.85341,"lon":2.3488}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Saint-Brieuc","zip":"22027","country":"France","geoPoint":{"lat":48.51513,"lon":-2.76838}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Toulouse","zip":"31059","country":"France","geoPoint":{"lat":43.60426,"lon":1.44367}},{"facility":"Hadassah Medical Center - Ein Karem","city":"Jerusalem","zip":"9112001","country":"Israel","geoPoint":{"lat":31.76904,"lon":35.21633}},{"facility":"Sheba Medical Center","city":"Tel Litwinsky","zip":"5265601","country":"Israel","geoPoint":{"lat":32.05096,"lon":34.84588}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Cona","zip":"44124","country":"Italy","geoPoint":{"lat":44.80583,"lon":11.7069}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Genova","zip":"16132","country":"Italy","geoPoint":{"lat":45.21604,"lon":11.87211}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Padua","zip":"35128","country":"Italy","geoPoint":{"lat":45.40797,"lon":11.88586}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Roma","zip":"00128","country":"Italy","geoPoint":{"lat":44.99364,"lon":11.10642}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Barcelona","zip":"08035","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Madrid","zip":"28034","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Seville","zip":"41013","country":"Spain","geoPoint":{"lat":37.38283,"lon":-5.97317}}]},"referencesModule":{"references":[{"pmid":"32694159","type":"DERIVED","citation":"Tolaney SM, Sahebjam S, Le Rhun E, Bachelot T, Kabos P, Awada A, Yardley D, Chan A, Conte P, Dieras V, Lin NU, Bear M, Chapman SC, Yang Z, Chen Y, Anders CK. A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor-Positive Breast Cancer. Clin Cancer Res. 2020 Oct 15;26(20):5310-5319. doi: 10.1158/1078-0432.CCR-20-1764. Epub 2020 Jul 21."}],"seeAlsoLinks":[{"label":"Click here for more information about this study: A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma that has Spread to the Brain","url":"https://lillytrialguide.com/en-US/studies/advanced-cancer/JPBO#?postal="}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.","infoTypes":["STUDY_PROTOCOL","SAP","CSR"],"timeFrame":"Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.","accessCriteria":"A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.","url":"https://vivli.org/"}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"Completers include participants who died or discontinued study treatment due to progressive disease and is in follow up.","groups":[{"id":"FG000","title":"Part A Abemaciclib: Hormone Receptor (HR+) HER2+ Breast Cancer","description":"Abemaciclib 200 milligram (mg) was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or in combination with endocrine therapy (ET). Participants with hormone receptor positive (HR+), hormone epidermal growth factor receptor 2 positive (HER2+) breast cancer receiving concurrent trastuzumab, 150 mg abemaciclib was given orally once every 12 hours on days 1-21 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met."},{"id":"FG001","title":"Part B Abemaciclib: HR+, HER2- Breast Cancer","description":"Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or in combination with endocrine therapy (ET).\n\nParticipants may continue to receive treatment until discontinuation criteria are met."},{"id":"FG002","title":"Part C Abemaciclib: Surgical Resection","description":"Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or for participants with breast cancer in combination with endocrine therapy (ET). Participants with HR+, HER2+ breast cancer, NSCLC, or melanoma with intracranial lesions for which surgical resection is clinically indicated receiving concurrent trastuzumab, gemcitabine, or pemetrexed, 150 mg abemaciclib was given orally once every 12 hours for 5-14 days prior to surgical resection. Dosing may resume following wound healing on a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met."},{"id":"FG003","title":"Part D Abemaciclib: Non-Small Cell Lung Cancer (NSCLC)","description":"Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle. Participants with NSCLC receiving concurrent gemcitabine or pemetrexed, 150 mg abemaciclib was given orally once every 12 hours on days 1-21 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met."},{"id":"FG004","title":"Part E Abemaciclib: Melanoma","description":"Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met."},{"id":"FG005","title":"Part F Abemaciclib: HR+ Breast Cancer, NSCLC, or Melanoma","description":"Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or for participants with breast cancer in combination with endocrine therapy (ET). Participants with HR+ (either HER2+ or HER2-) breast cancer, NSCLC, or melanoma and leptomeningeal metastases received concurrent trastuzumab, gemcitabine, or pemetrexed, 150 mg abemaciclib was given orally once every 12 hours on days 1-21 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"27"},{"groupId":"FG001","numSubjects":"58"},{"groupId":"FG002","numSubjects":"9"},{"groupId":"FG003","numSubjects":"28"},{"groupId":"FG004","numSubjects":"23"},{"groupId":"FG005","numSubjects":"17"}]},{"type":"Received at Least One Dose of Study Drug","achievements":[{"groupId":"FG000","numSubjects":"27"},{"groupId":"FG001","numSubjects":"58"},{"groupId":"FG002","numSubjects":"9"},{"groupId":"FG003","numSubjects":"28"},{"groupId":"FG004","numSubjects":"23"},{"groupId":"FG005","numSubjects":"17"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"23"},{"groupId":"FG001","numSubjects":"38"},{"groupId":"FG002","numSubjects":"6"},{"groupId":"FG003","numSubjects":"24"},{"groupId":"FG004","numSubjects":"19"},{"groupId":"FG005","numSubjects":"12"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"20"},{"groupId":"FG002","numSubjects":"3"},{"groupId":"FG003","numSubjects":"4"},{"groupId":"FG004","numSubjects":"4"},{"groupId":"FG005","numSubjects":"5"}]}],"dropWithdraws":[{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"7"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"1"},{"groupId":"FG005","numSubjects":"2"}]},{"type":"Sponsor Decision","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"8"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"2"},{"groupId":"FG004","numSubjects":"2"},{"groupId":"FG005","numSubjects":"1"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"5"},{"groupId":"FG002","numSubjects":"3"},{"groupId":"FG003","numSubjects":"2"},{"groupId":"FG004","numSubjects":"1"},{"groupId":"FG005","numSubjects":"2"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"All participants who received at least one dose of study drug.","groups":[{"id":"BG000","title":"Part A Abemaciclib: HR+, HER2+ Breast Cancer","description":"Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or in combination with endocrine therapy (ET). Participants with hormone receptor positive HR+, HER2+ breast cancer receiving concurrent trastuzumab, 150 mg abemaciclib was given orally once every 12 hours on days 1-21 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met."},{"id":"BG001","title":"Part B Abemaciclib: HR+, HER2- Breast Cancer","description":"Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or in combination with endocrine therapy (ET).\n\nParticipants may continue to receive treatment until discontinuation criteria are met."},{"id":"BG002","title":"Part C Abemaciclib: Surgical Resection","description":"Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or for participants with breast cancer in combination with endocrine therapy (ET). Participants with HR+, HER2+ breast cancer, NSCLC, or melanoma with intracranial lesions for which surgical resection is clinically indicated receiving concurrent trastuzumab, gemcitabine, or pemetrexed, 150 mg abemaciclib was given orally once every 12 hours for 5-14 days prior to surgical resection. Dosing may resume following wound healing on a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met."},{"id":"BG003","title":"Part D Abemaciclib: NSCLC","description":"Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle. Participants with NSCLC receiving concurrent gemcitabine or pemetrexed, 150 mg abemaciclib was given orally once every 12 hours on days 1-21 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met."},{"id":"BG004","title":"Part E Abemaciclib: Melanoma","description":"Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met."},{"id":"BG005","title":"Part F Abemaciclib: HR+ Breast Cancer, NSCLC, or Melanoma","description":"Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or for participants with breast cancer in combination with endocrine therapy (ET). Participants with HR+ (either HER2+ or HER2-) breast cancer, NSCLC, or melanoma and leptomeningeal metastases received concurrent trastuzumab, gemcitabine, or pemetrexed, 150 mg abemaciclib was given orally once every 12 hours on days 1-21 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met."},{"id":"BG006","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"27"},{"groupId":"BG001","value":"58"},{"groupId":"BG002","value":"9"},{"groupId":"BG003","value":"28"},{"groupId":"BG004","value":"23"},{"groupId":"BG005","value":"17"},{"groupId":"BG006","value":"162"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"49.9","spread":"10.9"},{"groupId":"BG001","value":"54.1","spread":"10.5"},{"groupId":"BG002","value":"57.0","spread":"17.9"},{"groupId":"BG003","value":"58.4","spread":"10.9"},{"groupId":"BG004","value":"55.1","spread":"14.4"},{"groupId":"BG005","value":"50.1","spread":"12.3"},{"groupId":"BG006","value":"54.0","spread":"12.1"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"27"},{"groupId":"BG001","value":"57"},{"groupId":"BG002","value":"8"},{"groupId":"BG003","value":"14"},{"groupId":"BG004","value":"11"},{"groupId":"BG005","value":"14"},{"groupId":"BG006","value":"131"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"14"},{"groupId":"BG004","value":"12"},{"groupId":"BG005","value":"3"},{"groupId":"BG006","value":"31"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"5"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"21"},{"groupId":"BG001","value":"42"},{"groupId":"BG002","value":"8"},{"groupId":"BG003","value":"20"},{"groupId":"BG004","value":"20"},{"groupId":"BG005","value":"14"},{"groupId":"BG006","value":"125"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"13"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"8"},{"groupId":"BG004","value":"2"},{"groupId":"BG005","value":"2"},{"groupId":"BG006","value":"32"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"5"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"7"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"17"},{"groupId":"BG001","value":"35"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"20"},{"groupId":"BG004","value":"22"},{"groupId":"BG005","value":"14"},{"groupId":"BG006","value":"115"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"2"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"15"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"7"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"2"},{"groupId":"BG006","value":"33"}]}]}]},{"title":"Region of Enrollment","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"title":"Canada","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"2"},{"groupId":"BG006","value":"3"}]}]},{"title":"Austria","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"1"}]}]},{"title":"Belgium","categories":[{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"3"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"18"}]}]},{"title":"United States","categories":[{"measurements":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"24"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"12"},{"groupId":"BG004","value":"7"},{"groupId":"BG005","value":"10"},{"groupId":"BG006","value":"71"}]}]},{"title":"Italy","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"9"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"15"}]}]},{"title":"Israel","categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"6"}]}]},{"title":"Australia","categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"9"}]}]},{"title":"France","categories":[{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"14"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"7"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"2"},{"groupId":"BG006","value":"32"}]}]},{"title":"Spain","categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"7"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR): Objective Intracranial Response Rate (OIRR)","description":"OIRR is the percentage of participants with a (CR) or (PR) based on the Response Assessment in Neuro-Oncology Brain Metastasis (RANO-BM) response criteria. CR is measurable target lesions, the disappearance of all central nervous system (CNS) target lesions for at least 4 weeks; no new lesions; no corticosteroids; stable or improved clinically. PR is at least a 30% decrease in the sum longest duration (LD) of CNS target lesions, taking as reference the baseline sum LD for at least 4 weeks; no new lesions; stable to decreased corticosteroid dose; stable or improved clinically. Nontarget lesions requires disappearance CNS non-target lesions and no new CNS lesions. Stable disease (SD) is less than (\\<)30% decrease relative to baseline but \\<20% increase in sum LD relative to nadir. Progressive disease (PD) is greater than or equal to (≥) 20% increase in sum LD relative to nadir and a relative increase of 20%, ≥1 lesion must increase by absolute value of ≥5 millimeter (mm).","populationDescription":"All participants who had evaluable OIRR data with at least one measurable brain lesion at baseline (per RANO-BM) and for whom at least one post-baseline overall response assessment for intracranial disease is available. Parts C and F were exploratory per protocol.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Baseline to Objective Disease Progression (Up to 36 Months)","groups":[{"id":"OG000","title":"Part A Abemaciclib: HR+, HER2+ Breast Cancer","description":"Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or in combination with endocrine therapy (ET). Participants with hormone receptor positive HR+, HER2+ breast cancer receiving concurrent trastuzumab, 150 mg abemaciclib was given orally once every 12 hours on days 1-21 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met."},{"id":"OG001","title":"Part B Abemaciclib: HR+, HER2- Breast Cancer","description":"Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or for in combination with endocrine therapy (ET).\n\nParticipants may continue to receive treatment until discontinuation criteria are met."},{"id":"OG002","title":"Part D Abemaciclib: NSCLC","description":"Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle. Participants with NSCLC receiving concurrent gemcitabine or pemetrexed, 150 mg abemaciclib was given orally once every 12 hours on days 1-21 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met."},{"id":"OG003","title":"Part E Abemaciclib: Melanoma","description":"Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"52"},{"groupId":"OG002","value":"23"},{"groupId":"OG003","value":"22"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"5.8"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With CR, PR, Stable Disease (SD), Progressive Disease (PD), or Not Evaluable (NE): Best Overall Intracranial Response (BOIR)","description":"Percentage of Participants with BOIR was categorized as CR, PR, SD, PD or NE, as defined by RANO-BM, from baseline until the earliest of objective progression according to brain metastases response criteria or start of new anticancer therapy. CR is measurable target lesions, the disappearance of all CNS target lesions for at least 4 weeks; no new lesions; no corticosteroids; stable or improved clinically. PR is at least a 30% decrease in the sum LD of CNS target lesions, taking as reference the baseline sum LD for at least 4 weeks; no new lesions; stable to decreased corticosteroid dose; stable or improved clinically. SD is \\<30% decrease relative to baseline but \\<20% increase in sum LD relative to nadir. PD is greater than or equal to (≥) 20% increase in sum LD relative to nadir and a relative increase of 20%, ≥1 lesion must increase by absolute value of ≥5 mm. NE is absent (no abnormality; normal), or non-evaluable (NE).","populationDescription":"All participants who had evaluable OIRR data with at least one measurable brain lesion at baseline (per RANO-BM) and for whom at least one post-baseline overall response assessment for intracranial disease is available. Parts C and F were exploratory per protocol.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Baseline to Earliest Objective Progression or Start of New Anticancer Therapy (Up to 36 Months)","groups":[{"id":"OG000","title":"Part A Abemaciclib: HR+, HER2+ Breast Cancer","description":"Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or in combination with endocrine therapy (ET). Participants with hormone receptor positive HR+, HER2+ breast cancer receiving concurrent trastuzumab, 150 mg abemaciclib was given orally once every 12 hours on days 1-21 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met."},{"id":"OG001","title":"Part B Abemaciclib: HR+, HER2- Breast Cancer","description":"Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or in combination with endocrine therapy (ET).\n\nParticipants may continue to receive treatment until discontinuation criteria are met."},{"id":"OG002","title":"Part D Abemaciclib: NSCLC","description":"Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle. Participants with NSCLC receiving concurrent gemcitabine or pemetrexed, 150 mg abemaciclib was given orally once every 12 hours on days 1-21 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met."},{"id":"OG003","title":"Part E Abemaciclib: Melanoma","description":"Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"52"},{"groupId":"OG002","value":"23"},{"groupId":"OG003","value":"22"}]}],"classes":[{"title":"Partial Response","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"5.8"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Stable Disease","categories":[{"measurements":[{"groupId":"OG000","value":"52.2"},{"groupId":"OG001","value":"65.4"},{"groupId":"OG002","value":"43.5"},{"groupId":"OG003","value":"31.8"}]}]},{"title":"Progressive Disease","categories":[{"measurements":[{"groupId":"OG000","value":"47.8"},{"groupId":"OG001","value":"28.8"},{"groupId":"OG002","value":"56.5"},{"groupId":"OG003","value":"68.2"}]}]},{"title":"Not Evaluable","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]}]},{"type":"SECONDARY","title":"Duration of CR or PR: Duration of Intracranial Response (DOIR)","description":"DOIR is measured from the date of first evidence of a confirmed response (CR or PR), as defined by RANO-BM, to the date objective progression or death from any cause. CR is measurable target lesions, the disappearance of all CNS target lesions for at least 4 weeks; no new lesions; no corticosteroids; stable or improved clinically. PR is at least a 30% decrease in the sum LD of CNS target lesions, taking as reference the baseline sum LD for at least 4 weeks; no new lesions; stable to decreased corticosteroid dose; stable or improved clinically. Participants who have neither progressed nor died were censored on the day of their last radiographic tumor assessment or on the date of response. PD is greater than or equal to (≥) 20% increase in sum LD relative to nadir and a relative increase of 20%, ≥1 lesion must increase by absolute value of ≥5 mm. DOIR was summarized using Kaplan-Meier estimates.","populationDescription":"All participants who had a confirmed intracranial response of CR or PR (per RANO-BM) and for whom at least one post-baseline overall intracranial response with a measurable duration is available. Parts C and F were exploratory per protocol.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"Months","timeFrame":"Date of CR or PR to Date of Objective Disease Progression or Death from Any Cause (Up to 36 Months)","groups":[{"id":"OG000","title":"Part A Abemaciclib: HR+, HER2+ Breast Cancer","description":"Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or in combination with endocrine therapy (ET). Participants with hormone receptor positive HR+, HER2+ breast cancer receiving concurrent trastuzumab, 150 mg abemaciclib was given orally once every 12 hours on days 1-21 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met."},{"id":"OG001","title":"Part B Abemaciclib: HR+, HER2- Breast Cancer","description":"Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or in combination with endocrine therapy (ET).\n\nParticipants may continue to receive treatment until discontinuation criteria are met."},{"id":"OG002","title":"Part D Abemaciclib: NSCLC","description":"Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle. Participants with NSCLC receiving concurrent gemcitabine or pemetrexed, 150 mg abemaciclib was given orally once every 12 hours on days 1-21 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met."},{"id":"OG003","title":"Part E Abemaciclib: Melanoma","description":"Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"8.8","lowerLimit":"3.0","upperLimit":"14.3"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Best Overall Intracranial Response (BOIR) of CR, PR, or SD: Intracranial Disease Control Rate (IDCR)","description":"Percentage of participants with BOIR of CR, PR, or SD: IDCR, as defined by RANO-BM is reported. CR is measurable target lesions, the disappearance of all central nervous system CNS target lesions for at least 4 weeks; no new lesions; no corticosteroids; stable or improved clinically. PR is at least a 30% decrease in the sum LD of CNS target lesions, taking as reference the baseline sum LD for at least 4 weeks; no new lesions; stable to decreased corticosteroid dose; stable or improved clinically. Nontarget lesions requires disappearance CNS non-target lesions and no new CNS lesions. SD is less than (\\<)30% decrease relative to baseline but \\<20% increase in sum LD relative to nadir. PD is greater than or equal to (≥) 20% increase in sum LD relative to nadir and a relative increase of 20%, ≥1 lesion must increase by absolute value of ≥5 mm.","populationDescription":"All participants who had evaluable OIRR data with at least one measurable brain lesion at baseline (per RANO-BM) and for whom at least one post-baseline overall response assessment. Parts C and F were exploratory per protocol.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Baseline to Disease Progression or Start of New Anticancer Therapy (Up to 36 Months)","groups":[{"id":"OG000","title":"Part A Abemaciclib: HR+, HER2+ Breast Cancer","description":"Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or in combination with endocrine therapy (ET). Participants with hormone receptor positive HR+, HER2+ breast cancer receiving concurrent trastuzumab, 150 mg abemaciclib was given orally once every 12 hours on days 1-21 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met."},{"id":"OG001","title":"Part B Abemaciclib: HR+, HER2- Breast Cancer","description":"Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or in combination with endocrine therapy (ET).\n\nParticipants may continue to receive treatment until discontinuation criteria are met."},{"id":"OG002","title":"Part D Abemaciclib: NSCLC","description":"Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle. Participants with NSCLC receiving concurrent gemcitabine or pemetrexed, 150 mg abemaciclib was given orally once every 12 hours on days 1-21 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met."},{"id":"OG003","title":"Part E Abemaciclib: Melanoma","description":"Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"52"},{"groupId":"OG002","value":"23"},{"groupId":"OG003","value":"22"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"52.2"},{"groupId":"OG001","value":"71.2"},{"groupId":"OG002","value":"43.5"},{"groupId":"OG003","value":"31.8"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With BOIR of CR, PR, or SD With Duration of SD for at Least 6 Months: Intracranial Clinical Benefit Rate (ICBR)","description":"ICBR is the percentage of participants with BOIR of CR, PR, or SD with duration of SD for at least 6 months, as defined by RANO-BM. CR is measurable target lesions, the disappearance of all CNS target lesions for at least 4 weeks; no new lesions; no corticosteroids; stable or improved clinically. PR is at least a 30% decrease in the sum LD of CNS target lesions, taking as reference the baseline sum LD for at least 4 weeks; no new lesions; stable to decreased corticosteroid dose; stable or improved clinically. SD is \\<30% decrease relative to baseline but \\<20% increase in sum LD relative to nadir. PD is greater than or equal to (≥) 20% increase in sum LD relative to nadir and a relative increase of 20%, ≥1 lesion must increase by absolute value of ≥5 mm.","populationDescription":"All participants who had evaluable OIRR data with at least one measurable brain lesion at baseline (per RANO-BM) and for whom at least one post-baseline overall response assessment for intracranial disease is available. Parts C and F were exploratory per protocol.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Baseline to Disease Progression or Start of New Anticancer Therapy (Up to 36 Months)","groups":[{"id":"OG000","title":"Part A Abemaciclib: HR+, HER2+ Breast Cancer","description":"Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or in combination with endocrine therapy (ET). Participants with hormone receptor positive HR+, HER2+ breast cancer receiving concurrent trastuzumab, 150 mg abemaciclib was given orally once every 12 hours on days 1-21 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met."},{"id":"OG001","title":"Part B Abemaciclib: HR+, HER2- Breast Cancer","description":"Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or in combination with endocrine therapy (ET).\n\nParticipants may continue to receive treatment until discontinuation criteria are met."},{"id":"OG002","title":"Part D Abemaciclib: NSCLC","description":"Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle. Participants with NSCLC receiving concurrent gemcitabine or pemetrexed, 150 mg abemaciclib was given orally once every 12 hours on days 1-21 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met."},{"id":"OG003","title":"Part E Abemaciclib: Melanoma","description":"Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"52"},{"groupId":"OG002","value":"23"},{"groupId":"OG003","value":"22"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.0"},{"groupId":"OG001","value":"26.9"},{"groupId":"OG002","value":"26.1"},{"groupId":"OG003","value":"9.1"}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS)","description":"OS was measured from baseline to the date of death from any cause. For each participant who is not known to have died as of the data-inclusion cutoff date for a particular analysis, OS was censored for that analysis at the date of last contact prior to the data inclusion cutoff date (contacts considered in the determination of last contact date include adverse event (AE) date, tumor assessment date, visit date, and last known alive date). OS was summarized using Kaplan-Meier estimates.","populationDescription":"All participants who received at least one dose of study drug. Parts C and F were exploratory per protocol. Censored participants in Part A = 4, Part B = 20, Part D = 4, Part E = 4.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Baseline to the Date of Death from Any Cause (Up to 5 Years)","groups":[{"id":"OG000","title":"Part A Abemaciclib: HR+, HER2+ Breast Cancer","description":"Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or in combination with endocrine therapy (ET). Participants with hormone receptor positive HR+, HER2+ breast cancer receiving concurrent trastuzumab, 150 mg abemaciclib was given orally once every 12 hours on days 1-21 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met."},{"id":"OG001","title":"Part B Abemaciclib: HR+, HER2- Breast Cancer","description":"Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or in combination with endocrine therapy (ET).\n\nParticipants may continue to receive treatment until discontinuation criteria are met."},{"id":"OG002","title":"Part D Abemaciclib: NSCLC","description":"Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle. Participants with NSCLC receiving concurrent gemcitabine or pemetrexed, 150 mg abemaciclib was given orally once every 12 hours on days 1-21 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met."},{"id":"OG003","title":"Part E Abemaciclib: Melanoma","description":"Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"58"},{"groupId":"OG002","value":"28"},{"groupId":"OG003","value":"23"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.06","lowerLimit":"4.21","upperLimit":"14.30"},{"groupId":"OG001","value":"13.38","lowerLimit":"9.60","upperLimit":"20.84"},{"groupId":"OG002","value":"7.13","lowerLimit":"3.65","upperLimit":"9.37"},{"groupId":"OG003","value":"2.93","lowerLimit":"1.22","upperLimit":"4.31"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a Best Response of CR or PR: Extracranial Objective Response Rate (EORR)","description":"The percentage of participants with a best response of CR or PR objective response rate is complete response (CR) + partial response (PR), as classified by the investigators according to the Response Evaluation Criteria In Solid Tumors (RECIST v1.1) guidelines. CR is disappearance of all target and non-target lesions; PR is ≥30% decrease in sum of longest diameter of target lesions. PD is defined as at least a 20% increase in the sum LD of CNS target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study) and the 20% increase must be at least one lesion must increase by an absolute value of ≥5 mm to be considered progression.","populationDescription":"All participants who received at least one dose of study drug. Parts C and F were exploratory per protocol.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Baseline to Disease Progression (Up to 36 Months)","groups":[{"id":"OG000","title":"Part A Abemaciclib: HR+, HER2+ Breast Cancer","description":"Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or in combination with endocrine therapy (ET). Participants with hormone receptor positive HR+, HER2+ breast cancer receiving concurrent trastuzumab, 150 mg abemaciclib was given orally once every 12 hours on days 1-21 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met."},{"id":"OG001","title":"Part B Abemaciclib: HR+, HER2- Breast Cancer","description":"Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or in combination with endocrine therapy (ET).\n\nParticipants may continue to receive treatment until discontinuation criteria are met."},{"id":"OG002","title":"Part D Abemaciclib: NSCLC","description":"Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle. Participants with NSCLC receiving concurrent gemcitabine or pemetrexed, 150 mg abemaciclib was given orally once every 12 hours on days 1-21 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met."},{"id":"OG003","title":"Part E Abemaciclib: Melanoma","description":"Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"58"},{"groupId":"OG002","value":"28"},{"groupId":"OG003","value":"23"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1.7"},{"groupId":"OG002","value":"3.6"},{"groupId":"OG003","value":"0"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a Best Overall Response of CR, PR, or SD: Extracranial Disease Control Rate (EDCR)","description":"Disease control rate (DCR) (CR+ PR+ SD) per RECIST v1.1. is defined as the percentage of participants with best overall response of CR, PR, or SD. CR is disappearance of all target and non-target lesions; PR is ≥30% decrease in sum of longest diameter of target lesions. PD is defined as at least a 20% increase in the sum LD of CNS target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study) and the 20% increase must be at least one lesion must increase by an absolute value of ≥5 mm to be considered progression.","populationDescription":"All participants who received at least one dose of study drug. Parts C and F were exploratory per protocol.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Baseline to Disease Progression or Start of New Anticancer Therapy (Up to 36 Months)","groups":[{"id":"OG000","title":"Part A Abemaciclib: HR+, HER2+ Breast Cancer","description":"Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or in combination with endocrine therapy (ET). Participants with hormone receptor positive HR+, HER2+ breast cancer receiving concurrent trastuzumab, 150 mg abemaciclib was given orally once every 12 hours on days 1-21 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met."},{"id":"OG001","title":"Part B Abemaciclib: HR+, HER2- Breast Cancer","description":"Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or in combination with endocrine therapy (ET).\n\nParticipants may continue to receive treatment until discontinuation criteria are met."},{"id":"OG002","title":"Part D Abemaciclib: NSCLC","description":"Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle. Participants with NSCLC receiving concurrent gemcitabine or pemetrexed, 150 mg abemaciclib was given orally once every 12 hours on days 1-21 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met."},{"id":"OG003","title":"Part E Abemaciclib: Melanoma","description":"Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"58"},{"groupId":"OG002","value":"28"},{"groupId":"OG003","value":"23"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"40.7"},{"groupId":"OG001","value":"51.7"},{"groupId":"OG002","value":"39.3"},{"groupId":"OG003","value":"26.1"}]}]}]},{"type":"SECONDARY","title":"Progression Free Survival (PFS) Bi-compartmental","description":"PFS was measured from baseline to objective progression (intracranial or extracranial) as defined by (RANO-BM.) or death from any cause. Participants who have neither progressed nor died were censored at the day of their last radiographic tumor assessment. PD is greater than or equal to (≥) 20% increase in sum LD relative to nadir and a relative increase of 20%, ≥1 lesion must increase by absolute value of ≥5 mm. PFS was summarized using Kaplan-Meier estimates.","populationDescription":"All participants who received at least one dose of study drug. Censored participants Part A = 1, Part B =2, Part D = 1 and Part E = 1. Parts C and F were exploratory per protocol.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"Baseline to Objective Disease Progression or Death from Any Cause (Up to 36 Months)","groups":[{"id":"OG000","title":"Part A Abemaciclib: HR+, HER2+ Breast Cancer","description":"Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or in combination with endocrine therapy (ET). Participants with hormone receptor positive HR+, HER2+ breast cancer receiving concurrent trastuzumab, 150 mg abemaciclib was given orally once every 12 hours on days 1-21 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met."},{"id":"OG001","title":"Part B Abemaciclib: HR+, HER2- Breast Cancer","description":"Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or in combination with endocrine therapy (ET).\n\nParticipants may continue to receive treatment until discontinuation criteria are met."},{"id":"OG002","title":"Part D Abemaciclib: NSCLC","description":"Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle. Participants with NSCLC receiving concurrent gemcitabine or pemetrexed, 150 mg abemaciclib was given orally once every 12 hours on days 1-21 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met."},{"id":"OG003","title":"Part E Abemaciclib: Melanoma","description":"Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"58"},{"groupId":"OG002","value":"28"},{"groupId":"OG003","value":"23"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.07","lowerLimit":"1.35","upperLimit":"3.32"},{"groupId":"OG001","value":"4.41","lowerLimit":"2.60","upperLimit":"5.46"},{"groupId":"OG002","value":"1.45","lowerLimit":"1.35","upperLimit":"2.76"},{"groupId":"OG003","value":"1.22","lowerLimit":"1.02","upperLimit":"1.55"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Neurologic Symptoms on the MD Anderson Inventory-Brain Tumor (MDASI-BT) Subscale","description":"The MDASI-BT is an instrument to assess multi-symptoms in participants with brain tumor metastases (including those with brain metastases secondary to breast cancer). The MDASI-BT of participants with a change from baseline is reported as mean core symptoms, mean brain tumor symptoms, and symptom groupings (mean focal neurologic deficit, mean generalized/disease status symptoms, and mean gastrointestinal symptoms). The mean of all symptom subscale items was calculated where 0 equals \"not present\" and 10 equals \"as bad as you can imagine.\" A change from baseline with negative values indicate improvement, positive values indicate worsening.","populationDescription":"All participants who received at least one dose of study drug and had at least 1 baseline and an evaluable post baseline assessment. Parts C and F were exploratory per protocol.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"units on a scale","timeFrame":"Baseline, Cycle 3 (Up to 63 Days)","groups":[{"id":"OG000","title":"Part A Abemaciclib: HR+, HER2+ Breast Cancer","description":"Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or for in combination with endocrine therapy (ET). Participants with hormone receptor positive HR+, HER2+ breast cancer receiving concurrent trastuzumab, 150 mg abemaciclib was given orally once every 12 hours on days 1-21 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met."},{"id":"OG001","title":"Part B Abemaciclib: HR+, HER2- Breast Cancer","description":"Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or in combination with endocrine therapy (ET).\n\nParticipants may continue to receive treatment until discontinuation criteria are met."},{"id":"OG002","title":"Part D Abemaciclib: NSCLC","description":"Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle. Participants with NSCLC receiving concurrent gemcitabine or pemetrexed, 150 mg abemaciclib was given orally once every 12 hours on days 1-21 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met."},{"id":"OG003","title":"Part E Abemaciclib: Melanoma","description":"Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"35"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"7"}]}],"classes":[{"title":"mean core symptom severity","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"35"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.98","spread":"0.86"},{"groupId":"OG001","value":"-0.17","spread":"0.99"},{"groupId":"OG002","value":"-0.38","spread":"1.19"},{"groupId":"OG003","value":"-0.53","spread":"0.62"}]}]},{"title":"mean brain tumor symptom severity","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"35"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.47","spread":"0.57"},{"groupId":"OG001","value":"-0.29","spread":"1.05"},{"groupId":"OG002","value":"-0.10","spread":"1.22"},{"groupId":"OG003","value":"0.31","spread":"1.11"}]}]},{"title":"mean focal neurologic deficit symptom severity","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"35"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.84","spread":"0.92"},{"groupId":"OG001","value":"-0.36","spread":"1.23"},{"groupId":"OG002","value":"-0.44","spread":"0.58"},{"groupId":"OG003","value":"0.54","spread":"1.16"}]}]},{"title":"mean generalized disease status","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"35"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.47","spread":"1.03"},{"groupId":"OG001","value":"0","spread":"1.39"},{"groupId":"OG002","value":"0.28","spread":"1.51"},{"groupId":"OG003","value":"0.01","spread":"0.89"}]}]},{"title":"mean gastrointestinal symptom","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"34"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.35","spread":"2.11"},{"groupId":"OG001","value":"0.40","spread":"1.91"},{"groupId":"OG002","value":"1.00","spread":"1.46"},{"groupId":"OG003","value":"0","spread":"0.29"}]}]}]},{"type":"SECONDARY","title":"Pharmacokinetics (PK): Steady State Minimum Concentration (Cmin) of Abemaciclib and Its Metabolites LSN2839567 (M2), LSN3106726 (M20), and LSN3106729 (M18)","description":"A PK plasma sample was taken prior to abemaciclib dose to analyze the minimum concentrations of abemaciclib and its metabolites (Cmin) - Individual Cmin values were averaged if there were 3 or more available data points, otherwise individual data are reported.","populationDescription":"All participants who had evaluable PK data.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"nanogram/milliliter (ng/mL)","timeFrame":"Parts A, B, D, E, F, Cycle 3, Day 1: Predose; Part C, Cycle 4, Day 1: Predose","groups":[{"id":"OG000","title":"Part A 150 mg Abemaciclib: HR+, HER2+ Breast Cancer","description":"Participants with HR+, HER2+ breast cancer received 150 mg abemaciclib orally once every 12 hours on days 1-21 of a 21-day cycle."},{"id":"OG001","title":"Part B 200 mg Abemaciclib: HR+, HER2- Breast Cancer","description":"Participants with HR+, HER2- breast cancer received 200 mg abemaciclib given orally once every 12 hours on days 1-21 of a 21-day cycle."},{"id":"OG002","title":"Part C 200 mg Abemaciclib: Surgical Resection","description":"Participants with HR+ breast cancer, NSCLC, or melanoma with intracranial lesions for which surgical resection is clinically indicated received 200 mg abemaciclib given orally once every 12 hours for 5-14 days prior to surgical resection."},{"id":"OG003","title":"Part D 200 mg Abemaciclib: NSCLC","description":"Participants with NSCLC received 200 mg abemaciclib given orally once every 12 hours on days 1-21 of a 21-day cycle."},{"id":"OG004","title":"Part E 200 mg Abemaciclib: Melanoma","description":"Participants with melanoma received 200 mg abemaciclib given orally once every 12 hours on days 1-21 of a 21-day cycle."},{"id":"OG005","title":"Part F 200 mg Abemaciclib: HR+ Breast Cancer, NSCLC, Melanoma","description":"Participants with HR+ (either HER2+ or HER2-) breast cancer, NSCLC, or melanoma and leptomeningeal metastases received 200 mg abemaciclib given orally once every 12 hours on days 1-21 of a 21-day cycle."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"4"}]}],"classes":[{"title":"Abemaciclib","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"133","spread":"13.4"},{"groupId":"OG001","value":"120","spread":"186"},{"groupId":"OG002","value":"NA","spread":"NA","comment":"N=1, Geometric mean and coefficient of variation (CV) were not calculated. Individual value reported: 256 ng/mL"},{"groupId":"OG003","value":"306","spread":"33.5"},{"groupId":"OG004","value":"NA","spread":"NA","comment":"N=2, Geometric mean and CV were not calculated. Individual values reported: 99.7 ng/mL and 222 ng/mL"},{"groupId":"OG005","value":"142","spread":"80.0"}]}]},{"title":"LSN2839567 (M2)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"72.6","spread":"8.23"},{"groupId":"OG001","value":"77.3","spread":"121"},{"groupId":"OG002","value":"NA","spread":"NA","comment":"N=1, Geometric mean and CV were not calculated. Individual value reported: 98.8 ng/mL"},{"groupId":"OG003","value":"100","spread":"77.5"},{"groupId":"OG004","value":"NA","spread":"NA","comment":"N=2, Geometric mean and CV were not calculated. Individual values reported: 61.6 ng/mL and 90.7 ng/mL"},{"groupId":"OG005","value":"68.5","spread":"150"}]}]},{"title":"LSN3106726 (M20)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"158","spread":"25.0"},{"groupId":"OG001","value":"133","spread":"160"},{"groupId":"OG002","value":"NA","spread":"NA","comment":"N=1, Geometric mean and CV were not calculated. Individual value reported: 181 ng/mL"},{"groupId":"OG003","value":"203","spread":"43.3"},{"groupId":"OG004","value":"NA","spread":"NA","comment":"N=2, Geometric mean and CV were not calculated. Individual values reported: 109 ng/mL and 172 ng/mL"},{"groupId":"OG005","value":"122","spread":"137"}]}]},{"title":"LSN3106729 (M18)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"36.8","spread":"39.3"},{"groupId":"OG001","value":"42.4","spread":"85.6"},{"groupId":"OG002","value":"NA","spread":"NA","comment":"N=1, Geometric mean and CV were not calculated. Individual value reported: 28.2 ng/mL"},{"groupId":"OG003","value":"28.9","spread":"108"},{"groupId":"OG004","value":"NA","spread":"NA","comment":"N=2, Geometric mean and CV were not calculated. Individual values reported: 22.2 ng/mL and 44.2 ng/mL"},{"groupId":"OG005","value":"27.0","spread":"242"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Up to 36 Months","description":"All participants who received at least one dose of study drug.","eventGroups":[{"id":"EG000","title":"Part A Abemaciclib: HR+, HER2+ Breast Cancer","description":"Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or in combination with Endocrine Therapy (ET). Participants with hormone receptor positive HR+, HER2+ breast cancer receiving concurrent trastuzumab, 150 mg abemaciclib was given orally once every 12 hours on days 1-21 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.","deathsNumAffected":23,"deathsNumAtRisk":27,"seriousNumAffected":6,"seriousNumAtRisk":27,"otherNumAffected":23,"otherNumAtRisk":27},{"id":"EG001","title":"Part B Abemaciclib: HR+, HER2- Breast Cancer","description":"Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or in combination with Endocrine Therapy (ET).\n\nParticipants may continue to receive treatment until discontinuation criteria are met.","deathsNumAffected":38,"deathsNumAtRisk":58,"seriousNumAffected":16,"seriousNumAtRisk":58,"otherNumAffected":55,"otherNumAtRisk":58},{"id":"EG002","title":"Part C Abemaciclib: Surgical Resection","description":"Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or for participants with breast cancer in combination with Endocrine Therapy (ET). Participants with HR+, HER2+ breast cancer, NSCLC, or melanoma with intracranial lesions for which surgical resection is clinically indicated receiving concurrent trastuzumab, gemcitabine, or pemetrexed, 150 mg abemaciclib was given orally once every 12 hours for 5-14 days prior to surgical resection. Dosing may resume following wound healing on a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.","deathsNumAffected":6,"deathsNumAtRisk":9,"seriousNumAffected":3,"seriousNumAtRisk":9,"otherNumAffected":8,"otherNumAtRisk":9},{"id":"EG003","title":"Part D Abemaciclib: NSCLC","description":"Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle. Participants with NSCLC receiving concurrent gemcitabine or pemetrexed, 150 mg abemaciclib was given orally once every 12 hours on days 1-21 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.","deathsNumAffected":24,"deathsNumAtRisk":28,"seriousNumAffected":8,"seriousNumAtRisk":28,"otherNumAffected":27,"otherNumAtRisk":28},{"id":"EG004","title":"Part E Abemaciclib: Melanoma","description":"Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.","deathsNumAffected":19,"deathsNumAtRisk":23,"seriousNumAffected":4,"seriousNumAtRisk":23,"otherNumAffected":16,"otherNumAtRisk":23},{"id":"EG005","title":"Part F: Abemaciclib HR+ Breast Cancer, NSCLC, or Melanoma","description":"Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or for participants with breast cancer in combination with Endocrine Therapy (ET). Participants with HR+ (either HER2+ or HER2-) breast cancer, NSCLC, or melanoma and leptomeningeal metastases received concurrent trastuzumab, gemcitabine, or pemetrexed, 150 mg abemaciclib was given orally once every 12 hours on days 1-21 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.","deathsNumAffected":12,"deathsNumAtRisk":17,"seriousNumAffected":7,"seriousNumAtRisk":17,"otherNumAffected":16,"otherNumAtRisk":17}],"seriousEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":17}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":27},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17}]},{"term":"Acute coronary syndrome","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17}]},{"term":"Cardiac failure","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17}]},{"term":"Myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17}]},{"term":"Glaucoma","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":27},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17}]},{"term":"Enterocolitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":27},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17}]},{"term":"Haemorrhoidal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17}]},{"term":"Lower gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":17}]},{"term":"Pancreatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17}]},{"term":"Upper gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":17}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":27},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":2,"numAffected":1,"numAtRisk":17}]},{"term":"General physical health deterioration","organSystem":"General disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":2,"numAffected":1,"numAtRisk":17}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17}]},{"term":"Hepatocellular injury","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17}]},{"term":"Jaundice cholestatic","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17}]},{"term":"Lung infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":17}]},{"term":"Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17}]},{"term":"Shunt infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":17}]},{"term":"Skin infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":28},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17}]},{"term":"Ankle fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17}]},{"term":"Fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":27},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":23},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":17}]},{"term":"Hypercalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":17}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17}]},{"term":"Tumour pain","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":17}]},{"term":"Aphasia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17}]},{"term":"Ataxia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17}]},{"term":"Brain oedema","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17}]},{"term":"Seizure","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":27},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":28},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG005","numEvents":3,"numAffected":2,"numAtRisk":17}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":17}]},{"term":"Confusional state","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":27},{"groupId":"EG001","numEvents":3,"numAffected":1,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17}]},{"term":"Mental status changes","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":17}]},{"term":"Acute kidney injury","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17}]},{"term":"Chronic kidney disease","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17}]},{"term":"Renal failure","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17}]},{"term":"Aspiration","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":17}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17}]},{"term":"Pneumonitis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17}]},{"term":"Pulmonary hypertension","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17}]},{"term":"Embolism","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17}]},{"term":"Shock haemorrhagic","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":17}]}],"otherEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":27},{"groupId":"EG001","numEvents":14,"numAffected":12,"numAtRisk":58},{"groupId":"EG002","numEvents":7,"numAffected":4,"numAtRisk":9},{"groupId":"EG003","numEvents":6,"numAffected":5,"numAtRisk":28},{"groupId":"EG004","numEvents":5,"numAffected":2,"numAtRisk":23},{"groupId":"EG005","numEvents":5,"numAffected":5,"numAtRisk":17}]},{"term":"Haemorrhagic diathesis","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17}]},{"term":"Leukocytosis","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":27},{"groupId":"EG001","numEvents":10,"numAffected":7,"numAtRisk":58},{"groupId":"EG002","numEvents":6,"numAffected":4,"numAtRisk":9},{"groupId":"EG003","numEvents":6,"numAffected":4,"numAtRisk":28},{"groupId":"EG004","numEvents":5,"numAffected":3,"numAtRisk":23},{"groupId":"EG005","numEvents":3,"numAffected":3,"numAtRisk":17}]},{"term":"Lymphopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":27},{"groupId":"EG001","numEvents":9,"numAffected":6,"numAtRisk":58},{"groupId":"EG002","numEvents":8,"numAffected":3,"numAtRisk":9},{"groupId":"EG003","numEvents":7,"numAffected":4,"numAtRisk":28},{"groupId":"EG004","numEvents":2,"numAffected":1,"numAtRisk":23},{"groupId":"EG005","numEvents":3,"numAffected":3,"numAtRisk":17}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":6,"numAtRisk":27},{"groupId":"EG001","numEvents":32,"numAffected":17,"numAtRisk":58},{"groupId":"EG002","numEvents":6,"numAffected":4,"numAtRisk":9},{"groupId":"EG003","numEvents":9,"numAffected":7,"numAtRisk":28},{"groupId":"EG004","numEvents":8,"numAffected":5,"numAtRisk":23},{"groupId":"EG005","numEvents":2,"numAffected":2,"numAtRisk":17}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":27},{"groupId":"EG001","numEvents":12,"numAffected":11,"numAtRisk":58},{"groupId":"EG002","numEvents":5,"numAffected":4,"numAtRisk":9},{"groupId":"EG003","numEvents":11,"numAffected":8,"numAtRisk":28},{"groupId":"EG004","numEvents":4,"numAffected":3,"numAtRisk":23},{"groupId":"EG005","numEvents":3,"numAffected":3,"numAtRisk":17}]},{"term":"Palpitations","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":17}]},{"term":"Hypoacusis","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":17}]},{"term":"Diplopia","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":17}]},{"term":"Eye pain","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":27},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17}]},{"term":"Photopsia","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":2,"numAffected":1,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":17}]},{"term":"Vision blurred","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":27},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":58},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":28},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG005","numEvents":2,"numAffected":2,"numAtRisk":17}]},{"term":"Abdominal distension","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":2,"numAffected":2,"numAtRisk":17}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":27},{"groupId":"EG001","numEvents":14,"numAffected":9,"numAtRisk":58},{"groupId":"EG002","numEvents":4,"numAffected":2,"numAtRisk":9},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":28},{"groupId":"EG004","numEvents":5,"numAffected":5,"numAtRisk":23},{"groupId":"EG005","numEvents":4,"numAffected":4,"numAtRisk":17}]},{"term":"Anal incontinence","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":17}]},{"term":"Ascites","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":27},{"groupId":"EG001","numEvents":11,"numAffected":9,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":7,"numAffected":7,"numAtRisk":28},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":23},{"groupId":"EG005","numEvents":3,"numAffected":3,"numAtRisk":17}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":26,"numAffected":15,"numAtRisk":27},{"groupId":"EG001","numEvents":100,"numAffected":45,"numAtRisk":58},{"groupId":"EG002","numEvents":6,"numAffected":4,"numAtRisk":9},{"groupId":"EG003","numEvents":21,"numAffected":15,"numAtRisk":28},{"groupId":"EG004","numEvents":6,"numAffected":5,"numAtRisk":23},{"groupId":"EG005","numEvents":6,"numAffected":6,"numAtRisk":17}]},{"term":"Dry mouth","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":27},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":28},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":17}]},{"term":"Dysphagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":17}]},{"term":"Gastritis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":17}]},{"term":"Gastrooesophageal reflux disease","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":27},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17}]},{"term":"Haemorrhoids","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":17}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":9,"numAtRisk":27},{"groupId":"EG001","numEvents":32,"numAffected":26,"numAtRisk":58},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":9},{"groupId":"EG003","numEvents":10,"numAffected":8,"numAtRisk":28},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG005","numEvents":10,"numAffected":7,"numAtRisk":17}]},{"term":"Oral pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":17}]},{"term":"Stomatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":27},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":17}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":7,"numAtRisk":27},{"groupId":"EG001","numEvents":31,"numAffected":20,"numAtRisk":58},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":9},{"groupId":"EG003","numEvents":4,"numAffected":4,"numAtRisk":28},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG005","numEvents":6,"numAffected":5,"numAtRisk":17}]},{"term":"Chills","organSystem":"General disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":27},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":9,"numAtRisk":27},{"groupId":"EG001","numEvents":31,"numAffected":28,"numAtRisk":58},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":9},{"groupId":"EG003","numEvents":16,"numAffected":11,"numAtRisk":28},{"groupId":"EG004","numEvents":4,"numAffected":4,"numAtRisk":23},{"groupId":"EG005","numEvents":9,"numAffected":9,"numAtRisk":17}]},{"term":"Gait disturbance","organSystem":"General disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":27},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":2,"numAffected":1,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17}]},{"term":"General physical health deterioration","organSystem":"General disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17}]},{"term":"Influenza like illness","organSystem":"General disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":27},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":58},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17}]},{"term":"Localised oedema","organSystem":"General disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":27},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17}]},{"term":"Malaise","organSystem":"General disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":58},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17}]},{"term":"Non-cardiac chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG001","numEvents":5,"numAffected":3,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":58},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":28},{"groupId":"EG004","numEvents":3,"numAffected":3,"numAtRisk":23},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":17}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":27},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":2,"numAffected":2,"numAtRisk":17}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":27},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":3,"numAffected":2,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17}]},{"term":"Ear infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":17}]},{"term":"Sinusitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":17}]},{"term":"Contusion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":58},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17}]},{"term":"Fall","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":27},{"groupId":"EG001","numEvents":6,"numAffected":4,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17}]},{"term":"Fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":17}]},{"term":"Incision site pain","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17}]},{"term":"Skin laceration","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":17}]},{"term":"Vascular access complication","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":27},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":58},{"groupId":"EG002","numEvents":7,"numAffected":6,"numAtRisk":9},{"groupId":"EG003","numEvents":4,"numAffected":2,"numAtRisk":28},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":23},{"groupId":"EG005","numEvents":2,"numAffected":2,"numAtRisk":17}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":27},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":58},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":9},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":28},{"groupId":"EG004","numEvents":4,"numAffected":4,"numAtRisk":23},{"groupId":"EG005","numEvents":3,"numAffected":2,"numAtRisk":17}]},{"term":"Blood alkaline phosphatase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":27},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG002","numEvents":4,"numAffected":3,"numAtRisk":9},{"groupId":"EG003","numEvents":5,"numAffected":2,"numAtRisk":28},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":17}]},{"term":"Blood bilirubin increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":27},{"groupId":"EG001","numEvents":6,"numAffected":5,"numAtRisk":58},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG003","numEvents":4,"numAffected":2,"numAtRisk":28},{"groupId":"EG004","numEvents":3,"numAffected":2,"numAtRisk":23},{"groupId":"EG005","numEvents":2,"numAffected":1,"numAtRisk":17}]},{"term":"Haemoglobin increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17}]},{"term":"International normalised ratio increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":17}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":58},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":9},{"groupId":"EG003","numEvents":5,"numAffected":4,"numAtRisk":28},{"groupId":"EG004","numEvents":2,"numAffected":1,"numAtRisk":23},{"groupId":"EG005","numEvents":2,"numAffected":2,"numAtRisk":17}]},{"term":"Weight increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":58},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":2,"numAffected":2,"numAtRisk":17}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":27},{"groupId":"EG001","numEvents":19,"numAffected":19,"numAtRisk":58},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":9},{"groupId":"EG003","numEvents":10,"numAffected":7,"numAtRisk":28},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":23},{"groupId":"EG005","numEvents":2,"numAffected":2,"numAtRisk":17}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":27},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":4,"numAffected":3,"numAtRisk":28},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":27},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":17}]},{"term":"Hyperkalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG002","numEvents":9,"numAffected":3,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17}]},{"term":"Hypermagnesaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":17}]},{"term":"Hypernatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17}]},{"term":"Hypoalbuminaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":27},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":2,"numAffected":2,"numAtRisk":17}]},{"term":"Hypocalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":27},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG002","numEvents":5,"numAffected":4,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":3,"numAffected":3,"numAtRisk":17}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":4,"numAtRisk":27},{"groupId":"EG001","numEvents":17,"numAffected":11,"numAtRisk":58},{"groupId":"EG002","numEvents":5,"numAffected":2,"numAtRisk":9},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":28},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG005","numEvents":2,"numAffected":2,"numAtRisk":17}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":27},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":58},{"groupId":"EG002","numEvents":9,"numAffected":2,"numAtRisk":9},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":28},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG005","numEvents":3,"numAffected":3,"numAtRisk":17}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":27},{"groupId":"EG001","numEvents":4,"numAffected":3,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG001","numEvents":4,"numAffected":3,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":28},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG005","numEvents":2,"numAffected":1,"numAtRisk":17}]},{"term":"Bone pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG001","numEvents":7,"numAffected":3,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG004","numEvents":3,"numAffected":2,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17}]},{"term":"Flank pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":58},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17}]},{"term":"Muscle spasms","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":58},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17}]},{"term":"Muscular weakness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":7,"numAtRisk":27},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":58},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":9},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":28},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":23},{"groupId":"EG005","numEvents":4,"numAffected":4,"numAtRisk":17}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG004","numEvents":3,"numAffected":3,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":27},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":58},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG004","numEvents":3,"numAffected":3,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17}]},{"term":"Amnesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":17}]},{"term":"Aphasia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":27},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17}]},{"term":"Balance disorder","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17}]},{"term":"Cognitive disorder","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":58},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17}]},{"term":"Disturbance in attention","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":17}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":27},{"groupId":"EG001","numEvents":8,"numAffected":8,"numAtRisk":58},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":17}]},{"term":"Dysarthria","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":28},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17}]},{"term":"Dysgeusia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":58},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":17}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":27},{"groupId":"EG001","numEvents":23,"numAffected":14,"numAtRisk":58},{"groupId":"EG002","numEvents":3,"numAffected":2,"numAtRisk":9},{"groupId":"EG003","numEvents":4,"numAffected":4,"numAtRisk":28},{"groupId":"EG004","numEvents":3,"numAffected":2,"numAtRisk":23},{"groupId":"EG005","numEvents":3,"numAffected":3,"numAtRisk":17}]},{"term":"Hemiparesis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":27},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17}]},{"term":"Neuropathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":27},{"groupId":"EG001","numEvents":19,"numAffected":12,"numAtRisk":58},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":9},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":28},{"groupId":"EG004","numEvents":2,"numAffected":1,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17}]},{"term":"Peripheral motor neuropathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":17}]},{"term":"Presyncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":17}]},{"term":"Seizure","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":27},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":2,"numAffected":1,"numAtRisk":28},{"groupId":"EG004","numEvents":3,"numAffected":3,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17}]},{"term":"Somnolence","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":27},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":17}]},{"term":"Tremor","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17}]},{"term":"Agitation","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":27},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":27},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":28},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17}]},{"term":"Confusional state","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":27},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":58},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":9},{"groupId":"EG003","numEvents":8,"numAffected":5,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":17}]},{"term":"Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":27},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":27},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":58},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":9},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":28},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17}]},{"term":"Acute kidney injury","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":28},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17}]},{"term":"Cystitis noninfective","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17}]},{"term":"Urinary incontinence","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":17}]},{"term":"Urinary retention","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":27},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":17}]},{"term":"Breast pain","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":27},{"groupId":"EG001","numEvents":7,"numAffected":5,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":17}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":27},{"groupId":"EG001","numEvents":9,"numAffected":9,"numAtRisk":58},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":9},{"groupId":"EG003","numEvents":5,"numAffected":5,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":2,"numAffected":2,"numAtRisk":17}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":27},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17}]},{"term":"Nasal congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":17}]},{"term":"Oropharyngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":2,"numAffected":1,"numAtRisk":17}]},{"term":"Sinus pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":17}]},{"term":"Alopecia","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":27},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":58},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17}]},{"term":"Dry skin","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":27},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":28},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":27},{"groupId":"EG001","numEvents":6,"numAffected":3,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":17}]},{"term":"Skin ulcer","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":27},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":2,"numAffected":1,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17}]},{"term":"Embolism","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":17}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG001","numEvents":4,"numAffected":2,"numAtRisk":58},{"groupId":"EG002","numEvents":3,"numAffected":2,"numAtRisk":9},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 22.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":58},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":28},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":17}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"GT60","restrictiveAgreement":true},"pointOfContact":{"title":"Chief Medical Officer","organization":"Eli Lilly and Company","email":"ClinicalTrials.gov@lilly.com","phone":"(800) 545-5979"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol: Protocol","date":"2014-11-11","uploadDate":"2019-08-30T14:33","filename":"Prot_000.pdf","size":876107},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2018-08-09","uploadDate":"2019-08-30T14:34","filename":"SAP_001.pdf","size":485162},{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol: Protocol Amendment (d)","date":"2019-02-08","uploadDate":"2019-08-30T14:38","filename":"Prot_002.pdf","size":5264438}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17","removedCountries":["New Zealand"]},"conditionBrowseModule":{"meshes":[{"id":"D001943","term":"Breast Neoplasms"},{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"},{"id":"D008545","term":"Melanoma"},{"id":"D001932","term":"Brain Neoplasms"}],"ancestors":[{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D001941","term":"Breast Diseases"},{"id":"D012871","term":"Skin Diseases"},{"id":"D017437","term":"Skin and Connective Tissue Diseases"},{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"},{"id":"D018358","term":"Neuroendocrine Tumors"},{"id":"D017599","term":"Neuroectodermal Tumors"},{"id":"D009373","term":"Neoplasms, Germ Cell and Embryonal"},{"id":"D009370","term":"Neoplasms by Histologic Type"},{"id":"D009380","term":"Neoplasms, Nerve Tissue"},{"id":"D018326","term":"Nevi and Melanomas"},{"id":"D012878","term":"Skin Neoplasms"},{"id":"D016543","term":"Central Nervous System Neoplasms"},{"id":"D009423","term":"Nervous System Neoplasms"},{"id":"D001927","term":"Brain Diseases"},{"id":"D002493","term":"Central Nervous System Diseases"},{"id":"D009422","term":"Nervous System Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C000590451","term":"abemaciclib"}]}},"hasResults":true}